AIT Bioscience Appoints New Group Leader, Ligand Binding Assay Department

FOR IMMEDIATE RELEASE
Contact: Bo Kowalczyk
Bo@aitbioscience.com
1-708-698-0190
 
INDIANAPOLIS, April 27, 2015 – AIT Bioscience, LLC announced today that Franklin P. Spriggs, BS, MS, will join the company as the group leader of the Ligand Binding Assays (LBA) department. Spriggs’ appointment further strengthens AIT Bioscience’s expertise in molecular biology analytical techniques in the LBA service line.
 
As LBA group leader, Spriggs will head all pharmacokinetic and biomarker research services for large molecule studies in clinical and pre-clinical stages. His immunochemistry expertise will further support the company’s immunogenicity research portfolio. His position oversees a significant proportion of AIT Biosciences’ throughput, running parallel to LC/MS-MS services for small molecules and serving directly under Chief Scientific Officer, Ron Shoup, PhD. His team is supported by the industry’s only fully integrated electronic laboratory environment.
 
“AIT Bioscience continues to build the Ligand Binding Assay department through continued execution of great science and implementation of innovation tools and platforms,” stated CEO Terri Pascarelli. “Frank’s expertise and leadership will drive that innovation and delivery of exceptional scientific consultation on LBA studies.” AIT Bioscience clients include US and international biopharma and animal health companies engaged in drug development of novel medical therapies.
 
Spriggs joins AIT Bioscience from Pfizer, where he held positions of increasing responsibility in the Pharmacokinetics, Dynamics and Metabolism department. Previously he worked at Amgen where he oversaw GLP bioanalysis and implemented automation projects for pharmacokinetics and drug metabolism. His expertise in biotech and pharmaceuticals includes extensive method development, validation, and analysis of protein therapeutics in pre-clinical and clinical phases of regulated drug development. His scientific focus includes pharmacokinetics, biomarkers, immunogenicity, quality assurance, clinical trial management and experimental design. Additionally, Spriggs has held leadership roles within the BIOTEC section of American Association of Pharmaceutical Scientists (AAPS).
 
Spriggs earned his BS in Microbiology from Ohio University and an MS in Quality Assurance and Regulatory Affairs from Temple University.
 
About AIT Bioscience, LLC
 
AIT Bioscience, LLC, headquartered in Indianapolis, Indiana, is an integrated contract research laboratory that provides continuous process monitoring and real-time quality control processes in Ligand Binding Assay (LBA) analytics for large molecule development alongside LC-MS/MS analytics for small molecules in pre-clinical and phase I – III clinical trials. The integration of these services, supported by a state-of-the-art smart electronic laboratory environment, allows AIT Bioscience to devise the best solution for its clients, across all bioanalytical methods. AIT Bioscience delivers robust analytical methods, highly skilled client consultation, efficient sample logistics and rapid sample analysis from pre-IND through investigational new drug (IND) and new drug application (NDA). For more information, visit www.aitbioscience.com.
 
###